<DOC>
	<DOCNO>NCT01538979</DOCNO>
	<brief_summary>The study evaluate efficacy safety BM32 grass pollen allergic subject . It test hypothesis either two dos BM32 lead sustain relief allergy symptom two year study period .</brief_summary>
	<brief_title>Phase II Study Grass Pollen Allergy Vaccine BM32</brief_title>
	<detailed_description>The present study design evaluate efficacy safety treatment recombinant vaccine BM32 two consecutive grass pollen season . Efficacy evaluation perform basis allergy symptom use relief medication well base immunological parameter . After patient assessment screen season , patient randomize one two dos BM32 placebo . Patients receive three injection BM32 pre-season one post-season boost injection maintain optimal allergen specific IgG response . Outcome measure season individually .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>Positive history grass pollen allergy Positive skin prick test reaction grass pollen extract Grass pollen specific IgE rPhl p 1/rPhl p 5 specific IgE ( &gt; 3 kUA/L ) Moderate severe symptom grass pollen allergy pollen peak Symptomatic perennial allergy Atopic dermatitis Pregnancy breast feed Women childbearing potential use medically accept birth control Autoimmune disease , immune defect , immune suppression Immune complex induce immunopathies Contra indication adrenaline Severe general malady , malignancy Patients longterm systematic corticosteroid , immune suppressive drug , tranquilizer psychoactive drug Contra indication skin prick test Bronchial asthma control low dose inhale corticosteroid Chronic use beta blocker Participation another clinical trial within one month prior study Participation SIT trial 2 year prio study Patients previous grass pollen SIT Risk noncompliance study procedure Use prohibit medication Depot corticosteroid 12 week prior enrolment Oral corticosteroid 8 week prior enrolment High dose inhale corticosteroid 4 week prior enrolment Use H1 antihistamines 3 day prior enrolment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Grass pollen allergy</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Recombinant vaccine</keyword>
	<keyword>Rhinitis , allergic , seasonal</keyword>
</DOC>